Kamada expands biosimilar portfolio with new launches
- Kamada (NASDAQ:KMDA) launched Ustekinumab-Kamada and Enoxaparin-Kamada commercially in Israel, expanding its marketed biosimilar line.
- The commercial introductions bring the biopharmaceutical company's active biosimilar portfolio to four fully approved interchangeable products.
- Management projects biosimilar revenues to reach $10 million by 2028 and $20 million to $25 million annually by 2030.
Kamada (NASDAQ:KMDA) expanded its commercial biosimilar portfolio in Israel with the market launch of Ustekinumab-Kamada and Enoxaparin-Kamada.
The two new commercial launches bring Kamada's active portfolio to four marketed products, all of which received regulatory approval as interchangeable biosimilars.
The company expects at least two additional biosimilars to become commercially available during 2027.
Meanwhile, management projects existing biosimilar sales of $4 million in 2026, scaling to approximately $10 million by 2028.
Kamada specializes in plasma-derived protein therapeutics and biosimilar distribution across global healthcare markets.
The company plans to commercialize at least 12 products across Israel and the Middle East and North Africa region by 2030, targeting $20 million to $25 million in annual biosimilar revenue.
